Laboratory revenue cycle management encompasses every operational process connecting clinical laboratory services to collected Medicare reimbursement – and in August 2026, it has become the most actionable lever available to laboratory executives preparing for a confirmed payment shift. The Consolidated Appropriations Act, 2026, signed February 3, 2026, delayed all PAMA-related Clinical Laboratory Fee Schedule (CLFS) rate reductions through December 31, 2026 – the seventh Congressional intervention since PAMA was enacted [1]. But the reprieve is temporary.

Account receivable services don’t often feature prominently in legal proceedings, but a recent case from Ardent Health b...
read more
Revenue cycle leaders questioning the value of outsourced medical billing services should consider the case of recent re...
read more
The pandemic “changed everything”—and “everything” should include how you answer the question, “should we outsource medi...
read more